StockMacro
Menu

Fennec Pharmaceuticals

$13.09 +32% in 6 monthsMarket cap $462.1M

FENC on XNAS, Health Care, Fennec Pharmaceuticals Inc., job postings

Measures activity, not value. Not investment advice.

Twelve-month revenue jumped 71% to $66.4M while shares rose 67% in the year.

  • GoodInstitutional holders rose to 118 from 105 last quarter
  • WatchNet income just $2M over twelve months, a 3.1% net margin

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
35
Website
fennecpharma.com
Listed
Nasdaq, US
Last results
24 Mar 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $19.6M, net income $4.6M.
Quarter to 31 Dec 2021: revenue –, net income -$4.4MQuarter to 31 Mar 2022: revenue –, net income -$3.7MQuarter to 30 Jun 2022: revenue –, net income -$5.1MQuarter to 30 Sep 2022: revenue –, net income -$8.1MQuarter to 31 Dec 2022: revenue –, net income -$6.9MQuarter to 31 Mar 2023: revenue $1.7M, net income -$6.1MQuarter to 31 Mar 2023: revenue $1.7M, net income -$6.1MQuarter to 30 Jun 2023: revenue $3.3M, net income -$5.4MQuarter to 30 Jun 2023: revenue $3.3M, net income -$5.4MQuarter to 30 Sep 2023: revenue $6.5M, net income -$1.9MQuarter to 30 Sep 2023: revenue $6.5M, net income -$1.9MQuarter to 31 Dec 2023: revenue –, net income -$28.5MQuarter to 31 Mar 2024: revenue $25.4M, net income $12.8MQuarter to 31 Mar 2024: revenue $25.4M, net income $12.8MQuarter to 30 Jun 2024: revenue $7.3M, net income -$5.6MQuarter to 30 Jun 2024: revenue $7.3M, net income -$5.6MQuarter to 30 Sep 2024: revenue $7.0M, net income -$5.7MQuarter to 30 Sep 2024: revenue $7.0M, net income -$5.7MQuarter to 31 Dec 2024: revenue $7.9M, net income -$2.0MQuarter to 31 Dec 2024: revenue $7.9M, net income -$2.0MQuarter to 31 Mar 2025: revenue $8.8M, net income -$1.2MQuarter to 31 Mar 2025: revenue $8.8M, net income -$1.2MQuarter to 30 Jun 2025: revenue $9.7M, net income -$3.2MQuarter to 30 Jun 2025: revenue $9.7M, net income -$3.2MQuarter to 30 Sep 2025: revenue $12.5M, net income -$638KQuarter to 30 Sep 2025: revenue $12.5M, net income -$638KQuarter to 31 Dec 2025: revenue $13.8M, net income -$4.8MQuarter to 31 Dec 2025: revenue $13.8M, net income -$4.8MQuarter to 31 Mar 2026: revenue $15.1M, net income $201KQuarter to 31 Mar 2026: revenue $15.1M, net income $201KQuarter to 30 Jun 2026: revenue $17.9M, net income $2.0MQuarter to 30 Jun 2026: revenue $17.9M, net income $2.0MQuarter to 30 Sep 2026: revenue $19.6M, net income $4.6MQuarter to 30 Sep 2026: revenue $19.6M, net income $4.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $28.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$19.6M$4.6M
30 Jun 2026$17.9M$2.0M
31 Mar 2026$15.1M$201K
31 Dec 2025$13.8M-$4.8M
30 Sep 2025$12.5M-$638K
30 Jun 2025$9.7M-$3.2M
31 Mar 2025$8.8M-$1.2M
31 Dec 2024$7.9M-$2.0M
30 Sep 2024$7.0M-$5.7M
30 Jun 2024$7.3M-$5.6M
31 Mar 2024$25.4M$12.8M
31 Dec 2023–-$28.5M
30 Sep 2023$6.5M-$1.9M
30 Jun 2023$3.3M-$5.4M
31 Mar 2023$1.7M-$6.1M
31 Dec 2022–-$6.9M
30 Sep 2022–-$8.1M
30 Jun 2022–-$5.1M
31 Mar 2022–-$3.7M
31 Dec 2021–-$4.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $66.4M $38.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +71% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $2.0M -$6.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 5.6% -12.0% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 3.1% -17.9% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $48.7M $21.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $19.4M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$2.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.39
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 228 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.0 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 9.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Fennec PharmaceuticalsFENC (this company) $462.1M2287.0+71%3.1%
RegenxbioRGNX $473.4Mloss3.1-4.6%-114%
Sana BiotechnologySANA $476.4Mloss–––
Ginkgo BioworksDNA $483.5Mloss4.8-33%-249%
IRulya TherapeuticsIRLA $432.4Mloss–––
Electra TherapeuticsETRA $509.8M––––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.6M

bought $0, sold $1.6M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+12%

118 13F filers vs 105

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

51%

18.0M shares held by 13F filers (30 Sep 2026) of 35.3M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.3%

454K shares sold short (30 Oct 2026) of 35.3M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.9

454K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.8%

488K shares sold short in the report before, 454K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

28%

28% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 39%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+57%

$19.6M vs $12.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $13.09 on 20 Nov 2026, +67% over 12 months (12-month range $5.77 to $13.58)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $9.9M in the last 12 months (the 12 months before: -$3.8M).
Revenue per quarter. Revenue $19.6M in the latest quarter, +57% on a year earlier.
Institutional holders (13F filers). 118 13F filers reported holding it in the latest 13F quarter, +46% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, capital spending per quarter, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
18 May 20268-K and other filingsDirector or officer change
28 Apr 20268-K and other filingsDirector or officer change
28 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Oct 20248-K and other filingsDirector or officer change
6 Aug 20248-K and other filingsDirector or officer change
1 Jul 20248-K and other filingsDirector or officer change
1 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Aug 20238-K and other filingsDirector or officer change
4 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Feb 2023Sharp changeShort interest spike: short interest spike, 1.0M vs usual 301K (2023-02-15); 3.4x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 900K vs usual 295K (2023-01-31); 3.1x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 701K vs usual 295K (2023-01-13); 2.2x the same period a year earlier
17 Jan 2023Sharp changeShort interest spike: short interest spike, 657K vs usual 295K (2022-12-30); 1.8x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 611K vs usual 295K (2022-11-30); 1.5x the same period a year earlier
31 Jan 20228-K and other filingsDirector or officer change
31 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2022: -$3K published
Month from 1 Dec 2022: -$487K published
Month from 1 May 2023: -$13K published
Month from 1 Jul 2023: -$298K published
Month from 1 Aug 2023: -$5K published
Month from 1 Nov 2023: -$196K published
Month from 1 Dec 2023: -$57K published
Month from 1 Jan 2024: -$316K published
Month from 1 Mar 2024: -$329K published
Month from 1 Apr 2024: -$2.9M published
Month from 1 May 2024: -$22K published
Month from 1 Jun 2024: -$16K published
Month from 1 Jul 2024: -$22K published
Month from 1 Aug 2024: -$15K published
Month from 1 Sep 2024: -$13K published
Month from 1 Oct 2024: -$18K published
Month from 1 Nov 2024: -$10K published
Month from 1 Dec 2024: -$54K published
Month from 1 Jan 2025: -$61K published
Month from 1 Feb 2025: -$75K published
Month from 1 Mar 2025: -$68K published
Month from 1 Apr 2025: -$59K published
Month from 1 May 2025: -$72K published
Month from 1 Jun 2025: -$78K published
Month from 1 Jul 2025: -$96K published
Month from 1 Aug 2025: -$81K published
Month from 1 Sep 2025: -$89K published
Month from 1 Oct 2025: -$751K published
Month from 1 Nov 2025: -$2.3M published
Month from 1 Dec 2025: -$7.6M published
Month from 1 Jan 2026: -$78K published
Month from 1 Feb 2026: -$80K published
Month from 1 Mar 2026: -$84K published
Month from 1 Apr 2026: -$69K published
Month from 1 May 2026: -$129K published
Month from 1 Jun 2026: -$94K published
Month from 1 Jul 2026: -$100K published
Month from 1 Aug 2026: -$979K published
Month from 1 Sep 2026: -$427K published
Month from 1 Nov 2026: -$240K published
Revenue per quarter
Quarter ended 31 Mar 2023: $1.7M; public on 15 May 2024
Quarter ended 30 Jun 2023: $3.3M; public on 14 Aug 2024
Quarter ended 30 Sep 2023: $6.5M; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $25.4M, +1413% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $7.3M, +118% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $7.0M, +7.0% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $7.9M; public on 27 Mar 2025
Quarter ended 31 Mar 2025: $8.8M, -66% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $9.7M, +33% on a year earlier; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $12.5M, +79% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $13.8M, +74% on a year earlier; public on 28 Mar 2026
Quarter ended 31 Mar 2026: $15.1M, +73% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $17.9M, +85% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $19.6M, +57% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 28; public on 14 Feb 2022
31 Mar 2022 report: 26; public on 16 May 2022
30 Jun 2022 report: 28; public on 15 Aug 2022
30 Sep 2022 report: 28; public on 14 Nov 2022
31 Dec 2022 report: 42; public on 14 Feb 2023
31 Mar 2023 report: 51; public on 15 May 2023
30 Jun 2023 report: 53; public on 14 Aug 2023
30 Sep 2023 report: 53; public on 14 Nov 2023
31 Dec 2023 report: 52; public on 14 Feb 2024
31 Mar 2024 report: 63; public on 15 May 2024
30 Jun 2024 report: 62; public on 14 Aug 2024
30 Sep 2024 report: 61; public on 14 Nov 2024
31 Dec 2024 report: 64; public on 14 Feb 2025
31 Mar 2025 report: 66; public on 15 May 2025
30 Jun 2025 report: 74; public on 14 Aug 2025
30 Sep 2025 report: 81; public on 14 Nov 2025
31 Dec 2025 report: 93; public on 17 Feb 2026
31 Mar 2026 report: 86; public on 15 May 2026
30 Jun 2026 report: 105; public on 14 Aug 2026
30 Sep 2026 report: 118; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2024: $11K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $240K (16 Nov 2026), 2.5× its normal reading; higher than 83% of its own history.
  • Insider net buying (open market): Insiders sold a net $9.9M in the last 12 months (the 12 months before: -$3.8M).
  • Revenue per quarter: Revenue $19.6M in the latest quarter, +57% on a year earlier.
  • Institutional holders (13F filers): 118 13F filers reported holding it in the latest 13F quarter, +46% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 84 insider trades

Last 90 days: 5 sales, $1.6M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Nov 2026Marco Maria BrugheraDirectorSellplanned in advance (10b5-1); after exercising options20,000$12.00$240KForm 4
16 Sep 2026Marco Maria BrugheraDirectorSellplanned in advance (10b5-1); after exercising options15,545$10.29$160KForm 4
1 Sep 2026Rosty RaykovFormer DirectorSellplanned in advance (10b5-1)10,000$12.11$121KForm 4
31 Aug 2026Pierre Sargis SayadChief Medical OfficerSell12,000$12.18$146KForm 4
28 Aug 2026Robert AndradeCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1); after exercising options75,000$11.78$884KForm 4
4 Aug 2026Rosty RaykovFormer DirectorSellplanned in advance (10b5-1)10,000$9.58$96KForm 4
2 Jul 2026Rosty RaykovFormer DirectorSellplanned in advance (10b5-1); after exercising options9,599$10.41$100KForm 4
2 Jun 2026Rosty RaykovDirectorSellplanned in advance (10b5-1); after exercising options9,747$9.62$94KForm 4

118 institutions reported shares at the end of Q3 2026, 51% of the shares outstanding; 21 opened a position, 8 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Rosalind Advisors, Inc.3.2M9.03%$34.0MNo change
AIGH Capital Management LLC2.5M7.08%$26.6M+13K+0.5%
BlackRock, Inc.2.0M5.76%$21.7M+306K+18%
Solas Capital Management, LLC1.4M4.06%$15.3M-456K-24%
AWM Investment Company, Inc.1.2M3.29%$12.4MNo change
Prospect Capital Advisors, LLC887K2.51%$9.4M+389K+78%
Vanguard Capital Management LLC839K2.38%$8.9MNo change
State Street Corp426K1.21%$4.5M-315-0.1%
Geode Capital Management, LLC409K1.16%$4.4M+6,495+1.6%
Essex Investment Management Co LLC319K0.90%$3.4MNew+319K

Company events

All 36 company events

In 12 months: 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
18 May 2026Director or officer change8-K
28 Apr 2026Director or officer change8-K
19 Nov 2025Signed a major agreement8-K
18 Nov 2025Signed a major agreement8-K
17 Nov 2025Signed a major agreement8-K
20 Dec 2024Signed a major agreement8-K
30 Oct 2024Director or officer change8-K
6 Aug 2024Director or officer change8-K

The 5 newest of 54 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 18 May 2026Filings record

    Director or officer change

  2. 28 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 28 Apr 2026Filings record

    Director or officer change

  4. 20 May 2025Insiders record

    Hackman Jeffrey S. (Chief Executive Officer) bought 15,000 shares of FENC ($104,602) (dated 19 May 2025)

  5. 30 Oct 2024Filings record

    Director or officer change

  6. 6 Aug 2024Filings record

    Director or officer change

  7. 1 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 1 Jul 2024Filings record

    Director or officer change

  9. 4 Apr 2024Insiders record

    Andrade Robert (CHIEF FINANCIAL OFFICER) bought 12,500 shares of FENC [not an open-market trade] (dated 3 Apr 2024)

  10. 4 Apr 2024Insiders record

    Raykov Rosty (CHIEF EXECUTIVE OFFICER) bought 29,167 shares of FENC [not an open-market trade] (dated 3 Apr 2024)

  11. 4 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 4 Aug 2023Filings record

    Director or officer change

  13. 28 Feb 2023Short interest and volume change

    had 1.0M shares sold short in the 15 Feb 2023 report, 3.4× the same report last year.

    Same report last year: 299K; its normal report is 301K.

    See the evidence
    This period
    1.0M (the 15 Feb 2023 report)
    Normal report (median of 24 earlier)
    301K
    Typical spread (median absolute deviation)
    130K
    How far from its usual level
    +3.7
    Same report last year
    299K
    History used
    1,874 days
    2022-02-15: 299K2022-02-28: 282K2022-03-15: 280K2022-03-31: 271K2022-04-14: 270K2022-04-29: 265K2022-05-13: 265K2022-05-31: 258K2022-06-15: 211K2022-06-30: 158K2022-07-15: 155K2022-07-29: 184K2022-08-15: 303K2022-08-31: 352K2022-09-15: 492K2022-09-30: 498K2022-10-14: 466K2022-10-31: 547K2022-11-15: 588K2022-11-30: 611K2022-12-15: 577K2022-12-30: 657K2023-01-13: 701K2023-01-31: 900K2023-02-15: 1.0M
    the 15 Feb 2023 report24 earlier reportsnormal: 301K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 10 Feb 2023Short interest and volume change

    had 900K shares sold short in the 31 Jan 2023 report, 3.1× the same report last year.

    Same report last year: 291K; its normal report is 295K.

    See the evidence
    This period
    900K (the 31 Jan 2023 report)
    Normal report (median of 24 earlier)
    295K
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +4.2
    Same report last year
    291K
    History used
    1,859 days
    2022-01-31: 291K2022-02-15: 299K2022-02-28: 282K2022-03-15: 280K2022-03-31: 271K2022-04-14: 270K2022-04-29: 265K2022-05-13: 265K2022-05-31: 258K2022-06-15: 211K2022-06-30: 158K2022-07-15: 155K2022-07-29: 184K2022-08-15: 303K2022-08-31: 352K2022-09-15: 492K2022-09-30: 498K2022-10-14: 466K2022-10-31: 547K2022-11-15: 588K2022-11-30: 611K2022-12-15: 577K2022-12-30: 657K2023-01-13: 701K2023-01-31: 900K
    the 31 Jan 2023 report24 earlier reportsnormal: 295K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 26 Jan 2023Short interest and volume change

    had 701K shares sold short in the 13 Jan 2023 report, 2.2× the same report last year.

    Same report last year: 315K; its normal report is 295K.

    See the evidence
    This period
    701K (the 13 Jan 2023 report)
    Normal report (median of 24 earlier)
    295K
    Typical spread (median absolute deviation)
    70K
    How far from its usual level
    +3.9
    Same report last year
    315K
    History used
    1,841 days
    2022-01-14: 315K2022-01-31: 291K2022-02-15: 299K2022-02-28: 282K2022-03-15: 280K2022-03-31: 271K2022-04-14: 270K2022-04-29: 265K2022-05-13: 265K2022-05-31: 258K2022-06-15: 211K2022-06-30: 158K2022-07-15: 155K2022-07-29: 184K2022-08-15: 303K2022-08-31: 352K2022-09-15: 492K2022-09-30: 498K2022-10-14: 466K2022-10-31: 547K2022-11-15: 588K2022-11-30: 611K2022-12-15: 577K2022-12-30: 657K2023-01-13: 701K
    the 13 Jan 2023 report24 earlier reportsnormal: 295K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 12 Jan 2023Short interest and volume change

    had 657K shares sold short in the 30 Dec 2022 report, 1.8× the same report last year.

    Same report last year: 360K; its normal report is 295K.

    See the evidence
    This period
    657K (the 30 Dec 2022 report)
    Normal report (median of 24 earlier)
    295K
    Typical spread (median absolute deviation)
    61K
    How far from its usual level
    +4.0
    Same report last year
    360K
    History used
    1,827 days
    2021-12-15: 360K2022-01-14: 315K2022-01-31: 291K2022-02-15: 299K2022-02-28: 282K2022-03-15: 280K2022-03-31: 271K2022-04-14: 270K2022-04-29: 265K2022-05-13: 265K2022-05-31: 258K2022-06-15: 211K2022-06-30: 158K2022-07-15: 155K2022-07-29: 184K2022-08-15: 303K2022-08-31: 352K2022-09-15: 492K2022-09-30: 498K2022-10-14: 466K2022-10-31: 547K2022-11-15: 588K2022-11-30: 611K2022-12-15: 577K2022-12-30: 657K
    the 30 Dec 2022 report24 earlier reportsnormal: 295K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 10 Dec 2022Short interest and volume change

    had 611K shares sold short in the 30 Nov 2022 report, 1.5× the same report last year.

    Same report last year: 417K; its normal report is 295K.

    See the evidence
    This period
    611K (the 30 Nov 2022 report)
    Normal report (median of 24 earlier)
    295K
    Typical spread (median absolute deviation)
    61K
    How far from its usual level
    +3.5
    Same report last year
    417K
    History used
    1,797 days
    2021-11-15: 449K2021-11-30: 417K2021-12-15: 360K2022-01-14: 315K2022-01-31: 291K2022-02-15: 299K2022-02-28: 282K2022-03-15: 280K2022-03-31: 271K2022-04-14: 270K2022-04-29: 265K2022-05-13: 265K2022-05-31: 258K2022-06-15: 211K2022-06-30: 158K2022-07-15: 155K2022-07-29: 184K2022-08-15: 303K2022-08-31: 352K2022-09-15: 492K2022-09-30: 498K2022-10-14: 466K2022-10-31: 547K2022-11-15: 588K2022-11-30: 611K
    the 30 Nov 2022 report24 earlier reportsnormal: 295K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 31 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 31 Jan 2022Filings record

    Director or officer change

  20. 10 Oct 2020Short interest and volume change

    had 1.4M shares sold short in the 30 Sep 2020 report, 9.1× the same report last year.

    Same report last year: 154K; its normal report is 554K.

    See the evidence
    This period
    1.4M (the 30 Sep 2020 report)
    Normal report (median of 24 earlier)
    554K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +4.3
    Same report last year
    154K
    History used
    1,006 days
    2019-09-30: 154K2019-10-15: 343K2019-10-31: 386K2019-11-15: 423K2019-11-29: 419K2019-12-13: 425K2019-12-31: 469K2020-01-15: 499K2020-01-31: 485K2020-02-14: 559K2020-02-28: 670K2020-03-13: 667K2020-03-31: 853K2020-04-15: 691K2020-04-30: 674K2020-05-15: 534K2020-05-29: 548K2020-06-15: 514K2020-06-30: 1.4M2020-07-15: 1.2M2020-07-31: 1.1M2020-08-14: 1.1M2020-08-31: 1.2M2020-09-15: 1.4M2020-09-30: 1.4M
    the 30 Sep 2020 report24 earlier reportsnormal: 554K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 25 Sep 2020Short interest and volume change

    had 1.4M shares sold short in the 15 Sep 2020 report, 8.7× the same report last year.

    Same report last year: 160K; its normal report is 541K.

    See the evidence
    This period
    1.4M (the 15 Sep 2020 report)
    Normal report (median of 24 earlier)
    541K
    Typical spread (median absolute deviation)
    131K
    How far from its usual level
    +4.3
    Same report last year
    160K
    History used
    991 days
    2019-09-13: 160K2019-09-30: 154K2019-10-15: 343K2019-10-31: 386K2019-11-15: 423K2019-11-29: 419K2019-12-13: 425K2019-12-31: 469K2020-01-15: 499K2020-01-31: 485K2020-02-14: 559K2020-02-28: 670K2020-03-13: 667K2020-03-31: 853K2020-04-15: 691K2020-04-30: 674K2020-05-15: 534K2020-05-29: 548K2020-06-15: 514K2020-06-30: 1.4M2020-07-15: 1.2M2020-07-31: 1.1M2020-08-14: 1.1M2020-08-31: 1.2M2020-09-15: 1.4M
    the 15 Sep 2020 report24 earlier reportsnormal: 541K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 11 Jul 2020Short interest and volume change

    had 1.4M shares sold short in the 30 Jun 2020 report, 1.5× the same report last year.

    Same report last year: 885K; its normal report is 477K.

    See the evidence
    This period
    1.4M (the 30 Jun 2020 report)
    Normal report (median of 24 earlier)
    477K
    Typical spread (median absolute deviation)
    162K
    How far from its usual level
    +3.7
    Same report last year
    885K
    History used
    914 days
    2019-06-28: 885K2019-07-15: 170K2019-07-31: 140K2019-08-15: 195K2019-08-30: 150K2019-09-13: 160K2019-09-30: 154K2019-10-15: 343K2019-10-31: 386K2019-11-15: 423K2019-11-29: 419K2019-12-13: 425K2019-12-31: 469K2020-01-15: 499K2020-01-31: 485K2020-02-14: 559K2020-02-28: 670K2020-03-13: 667K2020-03-31: 853K2020-04-15: 691K2020-04-30: 674K2020-05-15: 534K2020-05-29: 548K2020-06-15: 514K2020-06-30: 1.4M
    the 30 Jun 2020 report24 earlier reportsnormal: 477K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 7 May 2020Insiders record

    Southpoint GP, LP (ten percent owner) and 4 other(s) bought 80,000 shares of FENC ($500,000) (dated 6 May 2020)

  24. 5 May 2020Insiders record

    Essetifin SPA (ten percent owner) and 5 other(s) bought 768,000 shares of FENC ($4.8M) (dated 4 May 2020)

  25. 24 Sep 2019Filings record

    Director or officer change

  26. 9 Sep 2019Filings record

    Director or officer change

  27. 20 Jun 2019Filings record

    Director or officer change

  28. 19 Apr 2019Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 19 Apr 2019Filings record

    Director or officer change

  30. 30 Mar 2018Insiders record

    MANCHESTER MANAGEMENT CO LLC (ten percent owner) and 3 other(s) bought 40,600 shares of FENC ($72,304) (dated 29 Mar 2018)

  31. 30 Mar 2018Insiders record

    BESSER JAMES E (ten percent owner) and 4 other(s) bought 190,850 shares of FENC ($392,528) (dated 29 Mar 2018)

  32. 30 Mar 2018Insiders record

    MANCHESTER MANAGEMENT CO LLC (ten percent owner) and 3 other(s) bought 82,666 shares of FENC ($205,132) (dated 29 Mar 2018)

  33. 30 Mar 2018Insiders record

    MANCHESTER MANAGEMENT CO LLC (ten percent owner) and 4 other(s) bought 79,830 shares of FENC ($581,310) (dated 29 Mar 2018)

  34. 30 Mar 2018Insiders record

    MANCHESTER MANAGEMENT CO LLC (ten percent owner) and 4 other(s) bought 96,000 shares of FENC ($192,640) (dated 29 Mar 2018)

  35. 30 Mar 2018Insiders record

    BESSER JAMES E (ten percent owner) and 3 other(s) bought 102,960 shares of FENC ($170,046) (dated 29 Mar 2018)

  36. 30 Mar 2018Insiders record

    BESSER JAMES E (ten percent owner) and 3 other(s) bought 189,800 shares of FENC ($475,668) (dated 29 Mar 2018)

  37. 15 Dec 2017Insiders record

    Cavazza Preta Martina (ten percent owner) and 5 other(s) bought 294,115 shares of FENC ($2.5M) (dated 14 Dec 2017)

  38. 29 Sep 2017Filings record

    Director or officer change

  39. 31 Aug 2017Filings record

    Registered new securities for sale (S-1)

  40. 10 Aug 2017Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 43 entries; narrow the window or the kind of data to see older ones.

Not listed: 199 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001211583
Ticker
FENC
Domain
fennecpharma.com
Hq location
NC|RESEARCH TRIANGLE PARK|27709 (1 unverified)
Name
ADHEREX TECHNOLOGIES INC, Fennec Pharmaceuticals Inc.
Uei
LA59ZMYRRTJ6
  • SEC Form 13F institutional holdings333 data points30 Sep 2017 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)145 records28 Mar 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)883 data points30 Jun 1996 to 10 Nov 2026
  • SEC Form 4 insider transactions84 records, 280 data points14 Dec 2017 to 16 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4176 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards3 data points4 Jan 2024 to 4 Jan 2024